Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.

PLoS One · 2016 · PMC4910973 · PMID 27310205

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

near-significantno p-value reported

Of note, the benefit of FOLFOX7-FOLFIRI treatment compared to FOLFOX4 treatment yielded a near-significant difference for pain (HR 0.49 [0.22–1.06]) in TUDD analysis and reached statistical significance in TTD analysis (HR 0.41 [0.18–0.91]; S3 Table ).

also in 2,306 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.